AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-MEDICAL LABORATORIES
Caris Life Sciences, Inc. Common Stock
XNAS · usd
SIC 8071 · SERVICES-MEDICAL LABORATORIES
FIGI BBG00255V2P2
32.00▲ 0.29 (0.91%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
31.71
Day's Range
30.95 – 32.16
52-Week Range
14.19 – 33.13
Volume
2.3M
Avg Volume
4.5M
Share Statistics
Shares Outstanding
Employees
1,846
Exchange
XNAS
Listed
2025-06-18
Share count as of August 3, 2026

Caris Life Sciences, Inc. Common Stock (CAI) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Caris Life Sciences, Inc. Common Stock (CAI)
What is Caris Life Sciences, Inc. Common Stock's Market Cap?
Caris Life Sciences, Inc. Common Stock's Market Cap is $9.0B, based on as-reported figures from SEC (XBRL) filings.
What is Caris Life Sciences, Inc. Common Stock's Enterprise Value?
Caris Life Sciences, Inc. Common Stock's Enterprise Value is $9.3B, based on as-reported figures from SEC (XBRL) filings.
What is Caris Life Sciences, Inc. Common Stock's Trailing P/E?
Caris Life Sciences, Inc. Common Stock's Trailing P/E is 86.0×, based on as-reported figures from SEC (XBRL) filings.
What is Caris Life Sciences, Inc. Common Stock's Price / Sales?
Caris Life Sciences, Inc. Common Stock's Price / Sales is 9.1×, based on as-reported figures from SEC (XBRL) filings.
What is Caris Life Sciences, Inc. Common Stock's EV / Revenue?
Caris Life Sciences, Inc. Common Stock's EV / Revenue is 9.4×, based on as-reported figures from SEC (XBRL) filings.
What is Caris Life Sciences, Inc. Common Stock's EV / EBITDA?
Caris Life Sciences, Inc. Common Stock's EV / EBITDA is 53.6×, based on as-reported figures from SEC (XBRL) filings.
What is Caris Life Sciences, Inc. Common Stock's Revenue (TTM)?
Caris Life Sciences, Inc. Common Stock's Revenue (TTM) is $989.6M, based on as-reported figures from SEC (XBRL) filings.
What is Caris Life Sciences, Inc. Common Stock's Net Income (TTM)?
Caris Life Sciences, Inc. Common Stock's Net Income (TTM) is $105.1M, based on as-reported figures from SEC (XBRL) filings.
What is Caris Life Sciences, Inc. Common Stock's EBITDA?
Caris Life Sciences, Inc. Common Stock's EBITDA is $174.0M, based on as-reported figures from SEC (XBRL) filings.
What is Caris Life Sciences, Inc. Common Stock's Diluted EPS (TTM)?
Caris Life Sciences, Inc. Common Stock's Diluted EPS (TTM) is 0.37, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CAIAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Revenue:
Total revenue
YoY growth+45.4%+78.8%+125.4%+113.4%
Costs and operating expenses:
Selling and marketing expense
General and administrative expense (see note 9)
Research and development expense
Total costs and operating expenses
% of revenue89.8%97.6%69.8%84.9%
Income (Loss) from operations
% of revenue10.2%2.4%30.2%15.1%
Other expense, net:
Interest income
Interest expense
Changes in fair value of financial instruments
Other expense, net
Total other expense, net
Loss before income taxes and income tax benefit
Income tax benefit (expense)
Net loss
% of revenue-0.2%-0.2%28.0%11.2%
Net loss attributable to common shareholders basic
Net loss attributable to common shareholders diluted
Net loss per share attributable to common shareholders:
Net loss per share attributable to common shareholders, basic (in dollars per share)
Net loss per share attributable to common shareholders, diluted (in dollars per share)